BridgeBio Pharma, Inc.

A single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and

Alnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, b

One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up

Last year was a tough one for Bayer and 2025 is going to be even worse but CEO Bill Anderson has delivered an upbeat update for the beleaguered German group as it teeters on the patent cliff of Xarelt